IGC Pharma (IGC) Common Equity (2016 - 2025)
Historic Common Equity for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $8.1 million.
- Pharma's Common Equity rose 969.23% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 969.23%. This contributed to the annual value of $6.3 million for FY2025, which is 1353.64% down from last year.
- According to the latest figures from Q3 2025, Pharma's Common Equity is $8.1 million, which was up 969.23% from $6.1 million recorded in Q2 2025.
- In the past 5 years, Pharma's Common Equity ranged from a high of $32.8 million in Q1 2021 and a low of $6.1 million during Q2 2025
- Its 5-year average for Common Equity is $16.3 million, with a median of $14.1 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first soared by 3727.18% in 2021, then crashed by 5090.2% in 2024.
- Pharma's Common Equity (Quarter) stood at $29.5 million in 2021, then plummeted by 37.86% to $18.3 million in 2022, then crashed by 50.58% to $9.1 million in 2023, then plummeted by 30.86% to $6.3 million in 2024, then rose by 29.29% to $8.1 million in 2025.
- Its Common Equity stands at $8.1 million for Q3 2025, versus $6.1 million for Q2 2025 and $6.3 million for Q1 2025.